ICON reports Q3 2026 results, raises buyback authorization to $750 millionOct 27Quarterly updateIcon Plc
BARDA-sponsored Phase 2 H5 flu vaccine trial posts results comparing AS03 and MF59 adjuvantsJul 23Trial updateIcon Plc